112 related articles for article (PubMed ID: 22203759)
1. Comparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: lessons learned from a negative trial.
Konstantinopoulos PA; Cannistra SA
J Clin Oncol; 2012 Feb; 30(4):347-50. PubMed ID: 22203759
[No Abstract] [Full Text] [Related]
2. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy directly followed by poly(ADP-ribose) polymerase inhibition as an alternative to surgery in patients with BRCA-mutated ovarian cancer: a potential management strategy in the era of coronavirus disease 2019.
Vetter MH; Smrz SA; Copeland LJ; Cohn DE
Am J Obstet Gynecol; 2020 Sep; 223(3):469-470. PubMed ID: 32454030
[No Abstract] [Full Text] [Related]
4. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
5. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
[TBL] [Abstract][Full Text] [Related]
6. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
7. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
Audeh MW; Carmichael J; Penson RT; Friedlander M; Powell B; Bell-McGuinn KM; Scott C; Weitzel JN; Oaknin A; Loman N; Lu K; Schmutzler RK; Matulonis U; Wickens M; Tutt A
Lancet; 2010 Jul; 376(9737):245-51. PubMed ID: 20609468
[TBL] [Abstract][Full Text] [Related]
8. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
9. [Not Available].
Gladieff L; Lyonnet DS; Lortholary A; Leary A; Genestie C; Ray-Coquard I
Bull Cancer; 2017 May; 104 Suppl 1():S16-S23. PubMed ID: 28625311
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
Drew Y; Mulligan EA; Vong WT; Thomas HD; Kahn S; Kyle S; Mukhopadhyay A; Los G; Hostomsky Z; Plummer ER; Edmondson RJ; Curtin NJ
J Natl Cancer Inst; 2011 Feb; 103(4):334-46. PubMed ID: 21183737
[TBL] [Abstract][Full Text] [Related]
11. A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol.
Nicum S; Roberts C; Boyle L; Kopijasz S; Gourley C; Hall M; Montes A; Poole C; Collins L; Schuh A; Dutton SJ;
BMC Cancer; 2014 Dec; 14():983. PubMed ID: 25526776
[TBL] [Abstract][Full Text] [Related]
12. BRCA Mutation Status Is Not Associated With Increased Hematologic Toxicity Among Patients Undergoing Platinum-Based Chemotherapy for Ovarian Cancer.
Kotsopoulos J; Willows K; Trat S; Kim RH; Volenik A; Sun P; Narod SA; Boyd J; May T
Int J Gynecol Cancer; 2018 Jan; 28(1):69-76. PubMed ID: 29194191
[TBL] [Abstract][Full Text] [Related]
13. Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature.
Hoskins PJ; Gotlieb WH
CA Cancer J Clin; 2017 Nov; 67(6):493-506. PubMed ID: 28881380
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of poly(ADP-ribose) polymerase in BRCA mutation carriers.
Li S
N Engl J Med; 2009 Oct; 361(17):1707; author reply 1707-8. PubMed ID: 19846859
[No Abstract] [Full Text] [Related]
15. PARP inhibition in BRCA-mutated breast and ovarian cancers.
Chan SL; Mok T
Lancet; 2010 Jul; 376(9737):211-3. PubMed ID: 20656109
[No Abstract] [Full Text] [Related]
16. [Oncogenetics in the management of ovarian cancer: State-of-the art].
Caron O
Gynecol Obstet Fertil; 2015 May; 43(5):335-7. PubMed ID: 25824714
[No Abstract] [Full Text] [Related]
17. Hereditary ovarian cancer: biology, response to chemotherapy and prognosis.
Safra T
Womens Health (Lond); 2009 Sep; 5(5):543-53. PubMed ID: 19702453
[TBL] [Abstract][Full Text] [Related]
18. Do Ovarian Cancer Patients with a Family History of Cancer (Suspected BRCA1 or BRCA2 Mutation) Suffer Greater Chemotherapy Toxicity?
Egloff H; Jatoi A
Cancer Invest; 2016 Nov; 34(10):531-535. PubMed ID: 27791391
[TBL] [Abstract][Full Text] [Related]
19. Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.
Lorusso D; Tripodi E; Maltese G; Lepori S; Sabatucci I; Bogani G; Raspagliesi F
Drug Des Devel Ther; 2018; 12():1501-1509. PubMed ID: 29881257
[TBL] [Abstract][Full Text] [Related]
20. BRACAnalysis CDx as a companion diagnostic tool for Lynparza.
Gunderson CC; Moore KN
Expert Rev Mol Diagn; 2015; 15(9):1111-6. PubMed ID: 26292709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
